Its funny to read such unresearched posts ..... you have given no credence to AG selling down or the fact that the Nasal Spray component SPL7013 is already approved in many countries for more than one product for internal use..... all hype ROFL
Do you really think SPL would make an ASX announcement that a product will hit the market in FH CY2021 if things haven't progressed to a level that would indicate same ?
I guess next you will say they hoodwinked the Australian Government with the hype as well to knock out the other applicants vying for funding for a once in a hundred year pandemic and be one of only 5 companies to receive $1 million in funding for guess what - the Nasal Spray
If your focus on SPL is only on COVID-19 space then you also appear to have forgotten about the DEP Remdesivir results ..... we are one of the only companies I know of with more than one shot at goal for this awful virus .... happy for you to point me in the direction of others on the ASX with multiple products in the pipeline ?
As your gripe appears to be with the Nasal Spray and COVID-19 treatments I won't go into the DEP portfolio with multiple trials at present, but that is the main reason many of us invested in SPL in the first place as an FYI, so anything COVID-19 that comes to fruition is just a bonus - just sayin'
SPL Price at posting:
$1.62 Sentiment: Hold Disclosure: Held
